ISPOR 16th Annual International Meeting: PODIUM PRESENTATIONS
 

PODIUM PRESENTATIONS

PODIUM SESSION I

MONDAY, MAY 23, 2011 - 1:45PM-2:45PM

CANCER OUTCOMES RESEARCH

CN1

 

MONOTHERAPY OF ANDROGEN DEPRIVATION THERAPY VERSUS RADICAL PROSTATECTOMY AMONG VETERANS WITH LOCALIZED PROSTATE CANCER: A COMPARATIVE EFFECTIVENESS ANALYSIS OF RETROSPECTIVE COHORTS
Liu J, Shi L, Sartor O
Tulane University, New Orleans, LA, USA

CN2

 

ESTIMATED EFFECTS OF THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM ON CERVICAL CANCER MORTALITY
Ekwueme DU1, Uzunangelov V2, Hoerger T2, Saraiya M1, Miller J1, Hall I1, Benard V1, Royalty J1, Li C1
1Center for Disease Control and Prevention, Atlanta, GA, USA, 2RTI International, Research Triangle Park, NC, USA

CN3

 

THE VALUE OF RESEARCH FOR ERCC1 TESTING IN STAGE I NON-SMALL CELL LUNG CANCER
Roth J1, Carlson JJ2, Steuten L3, Veenstra D1
1University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3University of Twente, Enschede, The Netherlands

CN4

 

PALONOSETRON VERSUS OTHER 5-HYDROXYTRYPTAMINE3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING AMONG MEDICARE PATIENTS WITH CANCER
Craver C1, Gayle J1, Balu S2, Buchner D2
1Premier, Inc, Charlotte, NC, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA

COMPARATIVE EFFECTIVENESS RESEARCH

CO1

 

COMPARATIVE EFFECTIVENESS ANALYSIS OF TNF BLOCKERS IN RHEUMATOID ARTHRITIS (RA) PATIENTS IN A REAL-WORLD SETTING
Bonafede RP1, Pearson D2, Babich J3, Chastek B4, Becker L4, Watson C5, Chaudhari S6, Harrison DJ7, Gandra SR7
1Providence Arthritis Center, Portland, OR, USA, 2Ventura County Medical Center, Ventura, CA, USA, 3Carolina Bone & Joint, Charlotte, NC, USA, 4i3 Innovus, Eden Prairie, MN, USA, 5Amgen, Newbury Park, CA, USA, 6KForce Clinical Research, Tampa, FL, USA, 7Amgen Inc., Thousand Oaks, CA, USA

CO2

 

REAL-WORLD COST-EFFECTIVENESS ANALYSIS OF CANCER DRUGS: COMPARATIVE EFFECTIVENESS RESEARCH USING RETROSPECTIVE CANADIAN REGISTRY DATA BEFORE AND AFTER DRUG APPROVAL
Khor S1, Krahn M2, Hodgson D3, Bremner K4, Luo J5, Hoch J1

1Cancer Care Ontario, Toronto, ON, Canada, 2Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada, 3Princess Margaret Hospital, Toronto, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5The Institute For Clinical Evaluative Sciences, Toronto, ON, Canada

CO3

 

PROJECT LIBRA: A NEW ANALYTIC TOOL FOR COMPARATIVE EFFECTIVENESS ANALYSES OF MULTIPAYER CLAIMS DATABASES
Mark T1, Pepitone A2, Hatzmann M1, Navathe A3, Goodrich K3, Chang S1
1Thomson Reuters, Washington, DC, USA, 2Thomson Reuters, Santa Barbara, CA, USA, 3Assistant Secretary for Planning and Evaluation, Washington, DC, USA

CO4

 

POTENTIAL COST SAVINGS FROM COMPARATIVE EFFECTIVENESS RESEARCH: LESSONS FROM COURAGE STUDY
Bonakdar tehrani A, Howard D
Emory University, Atlanta, GA, USA

EFFECTS OF DRUG MANAGEMENT PROGRAMS ON PATIENTS

DM1

 

IMPACT OF A PHARMACY REFILL MANAGEMENT SYSTEM ON OUTCOMES IN END STAGE RENAL DISEASE (ESRD) PATIENTS
Rubin JL1, Wilson SM1, Golomb J2
1DaVita Clinical Research, Minneapolis, MN, USA, 2DaVita Rx, San Bruno, CA, USA

DM2

 

12-MONTH OUTCOMES OF A PHARMACIST-PROVIDED TELEPHONE MEDICATION THERAPY MANAGEMENT (MTM) PROGRAM
Moczygemba L1, Barner JC2, Gabrillo E3
1Virginia Commonwealth University, Richmond, VA, USA, 2The University of Texas at Austin, Austin, TX, USA, 3Scott & White Health Plan Prescription Services, Temple, TX, USA

DM3

 

IMPACT OF MONTHLY PRESCRIPTION CAP ON MEDICATION PERSISTENCY AMONG PATIENTS WITH DIABETES, HYPERTENSION, OR HYPERLIPIDEMIA
Wang CC, Wei D, Farley J
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

DM4

 

EVALUATION OF CLINICAL LABORATORY-PHARMACY LINKAGE DECISION SUPPORT IN THE USE OF POTASSIUM SUPPLEMENTS
Yu S, Galanter W, Lin FJ, Lambert B
University of Illinois at Chicago, Chicago, IL, USA

EMPLOYEE HEALTH & PRODUCTIVITY OUTCOMES RESEARCH

OR1

 

THE ASSOCIATION BETWEEN SELF-PERCEIVED COGNITIVE DIFFICULTIES AND LEVEL OF DEPRESSION AMONG EMPLOYEES WITH CURRENT DEPRESSION
Lawrence C1, Roy A2, Harikrishnan V2, Yu S2, Dabbous OH2
1Xcenda AmerisourceBergan Consulting Services, Palm Harbor, FL, USA, 2Takeda Pharmaceuticals International, Deerfield, IL, USA

OR2

 

ASSESSING THE RELATIONSHIP BETWEEN MEDICATION ADHERENCE AND EMPLOYEE PRODUCTIVITY
Loeppke R1, Haufle V2, Jinnett K3
1U.S. Preventive Medicine, Inc., Brentwood, TN, USA, 2Alere, Rosemont, IL, USA, 3Integrated Benefits Institute, San Francisco, CA, USA

OR3

 

THE DIRECT AND INDIRECT COSTS ASSOCIATED WITH HYPOGONADISM AMONG U.S. PRIVATELY-INSURED EMPLOYEES
Kaltenboeck A1, Foster S2, Thomas N2, Ivanova J1, Diener M1, Bergman R1, Birnbaum H3, Swindle R2
1Analysis Group, Inc., New York, NY, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Analysis Group, Inc., Boston, MA, USA

OR4

 

ASSOCIATIONS BETWEEN JOBLESSNESS AND ALL-CAUSE HEALTH SERVICES UTILIZATION IN US DIABETIC WORKING AGE ADULTS
Davis-Ajami ML1, Nahata M1, Seiber E1, Reardon G2, Balkrishnan R3
1The Ohio State University, Columbus, OH, USA, 2Informagenics, LLC, Worthington, OH, USA, 3University of Michigan, Ann Arbor, MI, USA

CASE STUDIES IN ADDRESSING SELECTION BIAS

SB1

 

COMPARISON OF DIFFERENCE-IN-DIFFERENCE, PROPENSITY SCORE MATCHING AND INSTRUMENTAL VARIABLES IN ESTIMATING COST DIFFERENCES BETWEEN TWO COHORTS
Cao Z, Song X
Thomson Reuters, Cambridge, MA, USA

SB2

 

ZEROS AND NON-REPORTEDHEALTHCARE AND WORKPLACE PRODUCTIVITY DATA: AN APPLICATION OF TWO-STAGE ESTIMATION TECHNIQUES MEASURING INPATIENT COSTS AND ABSENTEEISM ASSOCIATED WITH LOW BACK AND NECK PAIN
Simons WR1, Chow W2, Biondi D2, Benson C2, Kim M2
1Global Health Economics & Outcomes Research Inc,, Summit, NJ, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA

SB3

 

INNOVATIVE DESIGN FOR A COMPARATIVE EFFECTIVENESS STUDY OF SCHIZOPHRENIA TREATMENTS: ANALYSIS OF RECORD REVIEW DATA INCORPORATING RANDOMIZATION AND PROPENSITY SCORE MATCHING
McCarrier KP1, Durkin MB2, Dirani R2, Markowitz M2, Slabaugh SL2, Martin ML1
1Health Research Associates, Inc, Seattle, WA, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA

SB4

 

A METHODOLOGY FOR ASSESSING TREATMENT EFFECT IN THE PRESENCE OF DISEASE SEVERITY AND COMORBIDITY IN RETROSPECTIVE OBSERVATIONAL STUDIES
Kiri VA
PAREXEL International, Uxbridge, London, UK

PODIUM SESSION II

TUESDAY, MAY 24, 2011 - 8:30AM - 9:30AM

RESEARCH ON METHODS: COST-EFFECTIVENESS ANALYSIS

CE1

 

COST-EFFECTIVENESS SENSITIVITY ANALYSIS METHODS: A COMPARISON OF ONE-WAY SENSITIVITY, ANALYSIS OF COVARIANCE, AND EXPECTED VALUE OF PARTIAL PERFECT INFORMATION
Campbell J1, McQueen RB1, Libby A1, Briggs A2
1University of Colorado, Aurora, CO, USA, 2University of Glasgow, Glasgow, UK

CE2

 

A NOVEL WAY OF ESTIMATING COST-EFFECTIVENESS RATIOS FROM CLINICAL TRIALS WITH MISSING DATA: A SIMULATION STUDY
Gagnon DD1, Engelhart L2
1Thomson Reuters, Santa Barbara, CA, USA, 2DePuy, Inc., Raynham, MA, USA

CE3

 

COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ASSESSMENT: A GRAPHICAL WAY TO COMBINE THE TWO FOR THE AID OF DECISION MAKERS
Paulden M, Pham B
University of Toronto, Toronto, ON, Canada

CE4

 

USING DYNAMIC TRANSMISSION MODELS TO ESTIMATE THE COST EFFECTIVENESS OF VACCINES: FOUR DIFFERENT METHODS AND THEIR RELEVANCE FOR DECISION MAKERS
Mauskopf J1, Talbird SE1, Standaert B2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline Biologicals, Wavre, Belgium

RESEARCH ON METHODS: DATABASE ANALYSIS

DS1

 

INTEGRATING DATA SOURCES TO CONDUCT COMPREHENSIVE ONCOLOGY BASED OUTCOMES RESEARCH
Albright F1, Bollu V2, Kuo KL3, Raimundo K1, Barney R3, Stenehjem D3, Brixner D3
1University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3University of Utah, Salt Lake City, UT, USA

DS2

 

A VALIDATION STUDY OF ALGORITHMS FOR IDENTIFYING METASTATIC BREAST, LUNG, OR COLORECTAL CANCER IN ADMINISTRATIVE CLAIMS DATA
Whyte JL1, Engel-Nitz NM2, Teitelbaum A2, Gomez Rey G2, Kallich J1
1Amgen Inc., Thousand Oaks, CA, USA, 2i3 Innovus, Eden Prairie, MN, USA

DS3

 

AVAILABILITY OF LABORATORY RESULTS DATA IN A U.S. CLAIMS DATABASE
Horne LN, Ming EE, Doyle C
AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

DS4

 

BURDEN OF PROOF…PROOF OF PRINCIPLE: REPLICATION QUANTIFICATION, REPLICATION AND VALIDATION… STANDARDS OF EVIDENCE IN OUTCOMES RESEARCH SURROGATE ENDPOINTS FOR ALL-CAUSE MORTALITY
Simons WR
Global Health Economics & Outcomes Research Inc, Summit, NJ, USA

DRUG USE AND PATIENT SAFETY

DU1

 

COMPARATIVE SAFETY OF STIMULANT AND ATOMOXETINE ASSOCIATED WITH THE RISK OF SUBSTANCE USE DISORDER AMONG ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
Bhattacharjee S1, Chen H2, Bhatara V3, Aparasu RR2
1West Virginia University, Morgantown, WV, USA, 2University of Houston, Houston, TX, USA, 3University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA

DU2

 

PREVALENCE AND PREDICTORS OF POTENTIALLY SIGNIFICANT DRUG-DRUG INTERACTIONS IN THE ELDERLY
Dudash K1, Negri G2, Baccarini S3, Rabinowitz C1, Maio V1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Local Health Authority Parma, Parma, Italy, 3Ospedale di Fidenza - San Secondo, Fidenza, Parma, Italy

DU3

 

IMPACT OF THE FDA'S ANTIPSYCHOTIC BLACK BOX WARNING ON PSYCHOTROPIC DRUG PRESCRIBING IN ELDERLY PATIENTS WITH DEMENTIA IN OUTPATIENT AND OFFICE-BASED SETTINGS
Desai VC, Heaton PC, Kelton C
University of Cincinnati, Cincinnati, OH, USA

DU4

 

THE LONG TERM UTILIZATION OF STIMULANTS IN CHILDREN AND ADOLESCENTS: A MEDICAID STUDY
Sudharshan L, Chen H
University of Houston, Houston, TX, USA

INFECTION OUTCOMES RESEARCH

IN1

 

MEASUREMENT OF SYMPTOMS AND IMPACT OF INFLUENZA: DEVELOPMENT OF THE SYMPTOM INTENSITY AND IMPACT OF INFLUENZA QUESTIONNAIRE (FLU-IIQ)
Osborne RH1, Norquist J2, Elsworth G1, Busija L3, Mehta V4, Herring T4, Gupta S4
1Deakin University, Melbourne, Victoria, Australia, 2Merck Sharp & Dohme Corp, North Wales, PA, USA, 3The University of Melbourne, Melbourne, Victoria, Australia, 4Merck Research Laboratories, North Wales, PA, USA

IN2

 

ASSOCIATION BETWEEN DRUG TOLERABILITY AND ECONOMIC IMPACT FOR PROPHYLAXIS OF INVASIVE FUNGAL INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
Gao X1, Ji X1, Stephens JM1, Schlamm H2, Tarallo M2
1Pharmerit International, Bethesda, MD, USA, 2Pfizer Inc, New York, NY, USA

IN3

 

COSTS ASSOCIATED WITH HCV AND RELATED COMPLICATIONS IN THE UNITED STATES FROM A MANAGED CARE PAYER'S PERSPECTIVE
McAdam Marx C1, Hane CA2, Biskupiak J1, Deniz B3, McGarry L4, Brixner D1
1University of Utah, Salt Lake City, UT, USA, 2Ingenix, Eden Prairie, MN, USA, 3Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA, 4i3 Innovus, Medford, MA, USA

IN4

 

CARDIOVASCULAR DISEASE SCREENING IN HIV-INFECTED PATIENTS – A COST-EFFECTIVENESS ANALYSIS
Nolte JEH1, Neumann T2, Neumann A3, Manne J4, Mostardt S3, Abbara S5, Brady TJ5, Hoffmann U5, Gazelle GS1, Wasem J3, Goehler A1
1Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 2University Hospital Essen, Essen, Germany, 3University Duisburg-Essen, Essen, Germany, 4Harvard School of Public Health, Boston, MA, USA, 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

IMPACT OF MEDICATION COMPLIANCE

MC1

 

COMPARISON OF REFILL GAP ANALYSIS METHODOLOGIES IN A POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB OR ETANERCEPT
Carter C, Bolge S, Ingham M, Schmeichel-Mueller C
Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

MC2

 

ASSESSING PREDICTORS OF MEDICATION ADHERENCE IN UNCONDITIONAL QUANTILE REGRESSION FRAMEWORK
Borah B
Mayo Clinic, Rochester, MN, USA

MC3

 

IMPACT OF MULTIPLE MEDICATION COMPLIANCE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE II DIABETES AND COMORBID HYPERTENSION CONTROLLING FOR ENDOGENEITY BIAS
An JJ, Nichol MB
University of Southern California, Los Angeles, CA, USA

MC4

 

LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA
Lokhandwala T, Yang Y, Thumula V, Bentley JP, Strum M, Banahan BF, Null KD
University of Mississippi, University, MS, USA

PODIUM SESSION III

TUESDAY, MAY 24, 2011 - 9:45AM-10:45AM

HEALTH CARE DECISION-MAKER'S CASE STUDIES

CASE1

 

THE USE AND PERCEIVED BENEFITS OF ELECTRONIC PRESCRIBING BY BLUE CROSS BLUE SHIELD OF LOUISIANA PHYSICIANS
Soonthornsima O1, Campbell C2, Shi L2
1Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA, 2Tulane University, New Orleans, LA, USA

CASE2

 

IMPLEMENTING A VALUE-BASED FORMULARY PILOT IN A U.S. COMMERCIAL SELF- INSURED EMPLOYER GROUP
Watkins J1, Sullivan SD2, Wong E1, Yamamoto S1, Ramsey S3
1Premera Blue Cross, Mountlake Terrace, WA, USA, 2University of Washington, Seattle, WA, USA, 3Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA

CASE3

 

DETERMINING THE COST EFFECTIVENESS OF A HOSPITAL HEALTH SYSTEM'S USE OF REFERENCE LABORATORIES
Yoder K1, Zema C2
1Excela Health, Greensburg, PA, USA, 2St. Vincent College, McKenna School of Business, Economics and Government, Latrobe, PA, USA

CASE4

 

INTEGRATING OUTCOMES INTO DECISION-MAKING ON REIMBURSING HIGH COST DRUGS – A FUNDER CASE STUDY OF THE BIOLOGICAL AGENTS FOR TREATING RHEUMATOID ARTHRITIS
Mcgee SA, Nel C

Discovery Health, Johannesburg, South Africa

RESEARCH ON METHODS: ECONOMIC EVALUATIONS

EE1

 

SYSTEMATIC REVIEW OF GUIDELINES FOR HEALTH ECONOMIC EVALUATIONS
Melnyk P, Wagner M, Dourdin N, Rindress D
BioMedCom Consultants Inc., Dorval, QC, Canada

EE2

 

VALIDATION OF THE UPDATED CHARLSON COMORBIDITY INDEX (CCI) TO PREDICT HEALTHCARE UTILIZATION FOR DIABETIC PATIENTS USING ADMINISTRATIVE DATA
Cheng LI1, Rascati KL1, Trice S2, Lawson K1, Barner JC1
1The University of Texas at Austin, Austin, TX, USA, 2Department of Defense, Fort Sam Houston, TX, USA

EE3

 

PERFORMANCE OF DIFFERENT COMORBIDITY MEASURES IN PREDICTING HEALTHCARE EXPENDITURE IN PATIENTS WITH DEMENTIA
Johnson ML, Mehta S, Chitnis AS, Bhowmik D, Dwibedi N, Kamble P
University of Houston, Houston, TX, USA

EE4

 

BOOTSTRAPPING USED TO PROVIDE ROBUST MEAN AND VARIANCE ESTIMATES FOR COMPARING PATIENTS TREATED WITH LIRAGLUTIDE TO A LARGE COMPARISON COHORT
McAdam Marx C1, Ye X1, Bouchard J2, Aagren M2, Conner C3, Brixner D1
1University of Utah, Salt Lake City, UT, USA, 2Novo Nordisk Inc, Princeton, NJ, USA, 3Novo Nordisk, Redmond, WA, USA

EVOLVING CONCEPTS IN OUTCOMES RESEARCH

EV1

 

DEVELOPMENT OF A GUIDANCE FOR INCLUDING PATIENT-REPORTED OUTCOMES (PROS) IN POST-APPROVAL CLINICAL TRIALS OF ONCOLOGY DRUGS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)
Basch EM1, Abernethy A2, Mullins CD3, Tiglao MR4, Tunis SR4
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 2Duke University Medical Center, Durham, NC, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA, 4Center for Medical Technology Policy, Baltimore, MD, USA

EV2

 

PAYERS AND PROS: BEYOND QOL
Miller KL, Stevens CA
PAREXEL Consulting, Waltham, MA, USA

EV3

 

A COMPARATIVE EFFECTIVENESS INDEX TO INFORM CLINICAL DECISIONS
Horowicz-Mehler N1, Doyle J1, Arikian S2, Hagan M3
1Quintiles Global Consulting, Hawthorne, NY, USA, 2Genesis BioPharma, Hoboken, NJ, USA, 3New York, NY, USA

EV4

 

MORE BANG FOR YOUR BUCK: TAKE A RISK WHEN ANALYSING INTERVIEW DATA
Roberts G
Double Helix Consulting Group, London, UK

ANALYSIS OF MEDICARE POLICY AND RESOURCE USE

MD1

 

USING COST-EFFECTIVENESS INFORMATION TO ALLOCATE MEDICARE RESOURCES – HOW MUCH MORE HEALTH FOR THE MONEY?
Chambers JD1, Cohen JT1, Neumann PJ1, Lord J2, Buxton M2
1Tufts Medical Center, Boston, MA, USA, 2HERG, Brunel University, Uxbridge, Middlesex, UK

MD2

 

PRESCRIPTION DRUG COST AND USE IN THE MEDICARE PART D POPULATION - USES OF A NEW LIMITED DATA SET
Powers CA1, Varghese A1, Hsu VD2, O'Donnell J3, Schneider K3
1Centers for Medicare and Medicaid Services, Baltimore, MD, USA, 2Buccaneer, A Vangent Company, Owings Mills, MD, USA, 3Buccaneer, A Vangent Company, West Des Moines, IA, USA

MD3

 

EVALUATING THE WILLINGNESS-TO-PAY OF MEDICARE BENEFICIARIES FOR PART D PLAN ASSISTANCE
Patel RA, Walberg MP, Na J, Hsiou D, Panchal V, Woelfel JA, Galal SM, Carr-Lopez SM, Chan EK
University of the Pacific, Stockton, CA, USA

MD4

 

EVALUATION OF AN INTERVENTION TO REDUCE POLY-PHARMACY IN MEDICARE PART D
Livengood KB, Harrell T, Abarca J
WellPoint, Inc., Indianapolis, IN, USA

EXAMINING THE QALY

QA1

 

COST-EFFECTIVENESS OF DUTASTERIDE AS A CHEMOPREVENTION IN PROSTATE CANCER: REDUCE WITHIN-TRIAL ANALYSIS
Earnshaw SR1, Chirila C1, McDade C1, Black L2, Andriole GL3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA, 3Washington University School of Medicine in St. Louis, St. Louis, MO, USA

QA2

 

CROSS-WALKING CANCER-SPECIFIC INSTRUMENTS TO THE EQ-5D AND SF-6D
Teckle P1, Peacock S1, van der Hoek K1, Chia S2, Melosky B2, Gelmon K2
1Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada, 2Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

QA3

 

DOES COST-EFFECTIVENESS ANALYSIS DISCRIMINATE AGAINST PATIENTS WITH SHORTER LIFE EXPECTANCY?
Paulden M, Culyer AJ
University of Toronto, Toronto, ON, Canada

QA4

 

IS THE AIM OF THE HEALTH CARE SYSTEM TO MAXIMISE QALYS? AN INVESTIGATION OF ‘WHAT ELSE MATTERS' IN THE NHS.
Praet C1, Shah K2, Devlin N3, Sussex J3, Parkin D4, Appleby J5
1Merck, London, UK, 2Office of Health Economics, University of Sheffield, London, UK, 3Office of Health Economics, London, UK, 4NHS South East Coast, London, UK, 5King's Fund, London, UK